During the first quarter of 2011, Vulcan GMS, Inc. ( www.vulcangms.com ), a supplier of custom-made lead products , experienced pressure for faster delivery from radiation shielding customers. "Manufacturing time at Vulcan is among the fastest in our segment," said Tom Ray, President of Vulcan GMS. "So we had to look elsewhere to increase responsiveness. After assembling a multi-disciplinary team, we attacked the problem by applying a technique we developed for our quality system."
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2010. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.Teletypewriter (TTY): 1 877 303-3388"Our Government's investment towards this initiative will help transform western Canadian health research into marketable medical technologies that generate new economic opportunities and jobs, while also improving patient care for countless individuals," said the Honourable Leona Aglukkaq, Minister of Health and Minister of the Canadian Northern Economic Development Agency, on behalf of the Honourable Lynne Yelich, Minister of State for Western Economic Diversification."Alberta's talented medical researchers continue to develop products that are helping to save lives worldwide," said the Honourable Gene Zwozdesky, Minister of Alberta Health and Wellness. "Thanks to the collaborative efforts of our many partners in health and innovation, Alberta cancer patients will be among the first to benefit from a unique and innovative technology developed right here at Edmonton's Cross Cancer Institute - a truly world-class cancer research and treatment facility."Western Economic Diversification Canada works with the provinces, industry associations and communities to promote the development and diversification of the western economy, coordinates federal economic activities in the West and advances the interests of western Canadians in national decision making.In Phase II clinical studies, subjects with locally advanced disease who received the investigational therapy Multikine (Leukocyte Interleukin, Injection) as first-line investigational treatment were observed to have demonstrated a 33% increase in overall survival rate as compared to the overall survival rate that was determined from a review of 55 trials of the same cancer population, which were reported (in the scientific literature) between 1987 and 2007. However, no definitive conclusions can be drawn from these data about the potential efficacy profile of this investigational therapy. Moreover, further research is required, and these results must be confirmed in a well-controlled Phase III clinical trial of this investigational therapy that is currently in progress. Subject to completion of that Phase III trial and FDA’s review of our entire data set on this investigational therapy, CEL-SCI believes that these early-stage clinical trial results indicate the potential for this investigational therapy to be a breakthrough in the treatment of advanced primary head and neck cancer. The U.S. Food and Drug Administration also granted orphan drug status to Multikine (Leukocyte Interleukin, Injection) in the neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck.The good news was Vulcan uncovered a major improvement opportunity. McAteer said, "It existed in the window of time between receipt of an order and the moment that order could be officially acknowledged. For many reasons, the front-end process was taking five to 10 days between order receipt and acknowledgement. But that much time was needed only if we wanted to cling to suboptimal practices. It was clear we had to close that window," he said.
Contacts Vulcan GMS, Inc. Tom Trisco 414-645-2040 x 317 Email Contact Libby Communications Bill Libby 231-755-4111 Email Contact
No comments:
Post a Comment